Evotec (NASDAQ:EVO) Sets New 52-Week Low - Time to Sell?

Key Points

• Evotec shares fell to a new 52-week low of $1.80, last trading at $1.81 versus the prior close of $1.86. The stock remains below its 50-day and 200-day moving averages of $2.13 and $2.61, respectively.
• Analyst sentiment has weakened, with recent downgrades from Buy to Hold and a Sell rating from Weiss Ratings. The consensus rating is Hold, with an average price target of $3.00.
• Institutional investors made several purchases or increased holdings, but institutions and hedge funds own only 5.81% of the company. Evotec is a Germany-based biotechnology firm focused on drug discovery and development partnerships.

Evotec AG (NASDAQ:EVO - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $1.80 and last traded at $1.81, with a volume of 28171 shares traded. The stock had previously closed at $1.86.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Berenberg Bank lowered Evotec from a "buy" rating to a "hold" rating in a report on Thursday, July 16th. Weiss Ratings downgraded Evotec from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 25th. TD Cowen cut Evotec from a "buy" rating to a "hold" rating and set a $2.00 target price on the stock. in a research note on Wednesday, July 15th. Finally, HC Wainwright reduced their price target on shares of Evotec from $7.00 to $4.00 and set a "buy" rating for the company in a report on Wednesday, July 15th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $3.00.

Evotec Stock Performance

The firm has a 50-day moving average of $2.13 and a 200 day moving average of $2.61. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.33 and a quick ratio of 2.21.

Institutional Investors Weigh In On Evotec

Institutional investors have recently bought and sold shares of the stock. Optiver Holding B.V. increased its stake in Evotec by 598.4% during the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company's stock valued at $709,000 after buying an additional 242,973 shares during the period. WCM Investment Management LLC boosted its holdings in shares of Evotec by 12.1% in the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company's stock valued at $1,480,000 after acquiring an additional 67,917 shares in the last quarter. Apollon Wealth Management LLC bought a new position in shares of Evotec in the first quarter valued at approximately $28,000. SmartHarvest Portfolios LLC acquired a new position in shares of Evotec during the first quarter valued at approximately $44,000. Finally, XTX Topco Ltd raised its holdings in Evotec by 25.1% during the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company's stock worth $57,000 after purchasing an additional 3,709 shares in the last quarter. Institutional investors and hedge funds own 5.81% of the company's stock.

About Evotec

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.